

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): An agent for the prevention or treatment of a disease associated with hyperglycemia, comprising as an active ingredient an selective SGLT1 inhibitor wherein the active ingredient and/or its metabolite exhibit an SGLT1 inhibitory effect substantially showing no GLUT2 and/or GLUT5 inhibitory effect.
2. (currently amended): An agent for the prevention or treatment as claimed in claim 1, wherein the active ingredient and/or its metabolite exhibit an SGLT1 inhibitory effect substantially showing no inhibitory effect on absorbing fructose through the small intestine is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.
3. (currently amended): An agent for the prevention or treatment as claimed in claim 1, wherein the dosage form is an oral agent.
4. (currently amended): An agent for the prevention or treatment as claimed in claim 1, wherein the disease associated with hyperglycemia is diabetes.
5. (currently amended): An agent for the prevention or treatment as claimed in claim 4, wherein the diabetes is postprandial hyperglycemia.

6. (currently amended): An agent for the prevention or treatment as claimed in claim 1, wherein the disease associated with hyperglycemia is impaired glucose tolerance.
7. (currently amended): An agent for the prevention or treatment as claimed in claim 1, wherein the disease associated with hyperglycemia is diabetic complications.
8. (currently amended): An agent for the prevention or treatment as claimed in claim 1, wherein the disease associated with hyperglycemia is obesity.
9. (currently amended): A method for the prevention or treatment of a disease associated with hyperglycemia, which comprises administering an effective amount of an ana selective SGLT1 inhibitor wherein the active ingredient and/or its metabolite exhibit an SGLT1 inhibitory effect substantially showing no GLUT2 and/or GLUT5 inhibitory effect.
10. (currently amended): A method for the prevention or treatment as claimed in claim 9, wherein the active ingredient and/or its metabolite exhibit an SGLT1 inhibitory effect substantially showing no inhibitory effect on absorbing fructose through the small intestine selective SGLT1 inhibitor is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.
11. (currently amended): A method for the prevention or treatment as claimed in claim 9, wherein the dosage form is an oral agent.

12. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 9, wherein the disease associated with hyperglycemia is diabetes.

13. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 12, wherein the diabetes is postprandial hyperglycemia.

14. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 9, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

15. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 9, wherein the disease associated with hyperglycemia is diabetic complications.

16. (currently amended): A method for the ~~prevention or~~ treatment as claimed in claim 9, wherein the disease associated with hyperglycemia is obesity;

17. (currently amended): A method for the manufacture of a pharmaceutical composition for the ~~prevention or~~ treatment of a disease associated with hyperglycemia, which method comprises blending the ~~selective~~ SGLT1 inhibitor of claim 1 with a pharmaceutically acceptable additive.

18. (currently amended): A method as claimed in claim 17, wherein the ~~selective~~ SGLT1 inhibitor is an SGLT1 inhibitor substantially showing no inhibitory effect on absorbing fructose through the small intestine~~GLUT2 and/or GLUT5 inhibitory effect~~.

19. (currently amended): A method as claimed in claim 17, wherein the composition is an oral agent.

20. (currently amended): A method as claimed in claim 17, wherein the disease associated with hyperglycemia is diabetes.

21. (currently amended): A method as claimed in claim 20, wherein the diabetes is postprandial hyperglycemia.

22. (currently amended): A method as claimed in claim 17, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

23. (currently amended): A method as claimed in claim 17, wherein the disease associated with hyperglycemia is diabetic complications.

24. (currently amended): A method as claimed in claim 17, wherein the disease associated with hyperglycemia is obesity.

25. (currently amended): An agent for the prevention or treatment as claimed in claim 2, wherein the dosage form is an oral agent.

26. (currently amended): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is diabetes.

27. (currently amended): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is diabetes.

28. (currently amended): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

29. (currently amended): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

30. (currently amended): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is diabetic complications.

31. (currently amended): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is diabetic complications.

32. (currently amended): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is obesity.

33. (currently amended): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is obesity.

34. (currently amended): A method for the prevention or treatment as claimed in claim 10, wherein the dosage form is an oral agent.

35. (currently amended): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is diabetes.

36. (currently amended): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is diabetes.

37. (currently amended): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

38. (currently amended): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

39. (currently amended): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is diabetic complications.

40. (currently amended): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is diabetic complications.

41. (currently amended): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is obesity.

42. (currently amended): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is obesity;

43. (previously presented): A method as claimed in claim 18, wherein the composition is an oral agent.

44. (previously presented): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is diabetes.

45. (previously presented): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is diabetes.

46. (previously presented): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

47. (previously presented): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

48. (previously presented): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is diabetic complications.

49. (previously presented): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is diabetic complications.

50. (currently amended): A method/use as claimed in claim 18, wherein the disease associated with hyperglycemia is obesity.

51. (previously presented): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is obesity.